Dementia: Is new drug a major breakthrough?
LMTX slows Alzheimer's progression - but it doesn't work on everyone and experts are urging caution
A new drug appears to slow down the progression of Alzheimer's disease – but only in certain cases.
Some scientists have hailed the results of the trial as a major breakthrough in a field that has seen little advancement in decades, but others are far more sceptical.
What is it and how does it work?
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
LMTX is taken twice a day in tablet form. In the trial, it was used to treat 891 patients with mild to moderate Alzheimer's for 18 months, with the results presented at a conference in Toronto, Canada.
It is the first time a major drug trial has targeted tau tangles – abnormal clumps of protein that disrupt brain function – instead of beta-amyloid, a different type of protein that forms plaques as it accumulates in the brain, the New Scientist reports.
"The success of the LMTX trial suggests that tau tangles might be the main cause of Alzheimer's symptoms," it says.
How successful is it?
Overall, the trial was a flop as there appeared to be no benefit to taking LMTX, says the BBC's health and science correspondent, James Gallagher.
"However, an analysis on just the 15 per cent of the patients who had not already been taking drugs to help manage their symptoms showed a benefit," he adds. "In this tiny subset of patients, tests showed thinking power was maintained and MRI scans found the death of brain cells was reduced."
Claude Wischik, the co-founder of TauRx Pharmaceuticals, which developed the drug, said the results were unprecedented. "On the whole, [it] slowed progression by about 80 per cent," he says.
Though further testing is needed, LMTX has helped people get back to their daily lives, he says: "A wife of a patient told me her husband suddenly got up and fixed the garden fence, which he'd needed to do for years."
What has the reaction been?
The discovery was hailed by many, with the US Alzheimer's Association describing it as "a significant event" in the history of dementia research.
"In a field that has been plagued by consistent failures of novel drug candidates in late-stage clinical trials and where there has been no practical therapeutic advance for over a decade, I am excited," said Dr Serge Gauthier, the director of the Alzheimer's Disease Research Unit at McGill University, Canada.
Others, however, have urged caution. Alzheimer's Research UK's Dr David Reynolds said he was concerned LMTX appeared not to work alongside other medications.
"The data suggests it is slowing down the disease, but the important caveat is these small numbers," he said.
"It is encouraging, but we need more data and will have to run a study with it as just a monotherapy [on its own]," he added. "It will still be years from reaching patients, even assuming it works."
Dr Rachelle Doody, the director of the Alzheimer's disease and Memory Disorders Center at Baylor College of Medicine in Texas, was even more pessimistic. "To present it to the public now as a promising approach seems unjustified," she told the New York Times.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
How Tehran became the world's nose job capital
Under the radar Iranian doctors raise alarm over low costs, weak regulation and online influence of 'Western beauty standards'
By Harriet Marsden, The Week UK Published
-
Africa's renewed battle against female genital mutilation
Under the radar Campaigners call for ban in Sierra Leone after deaths of three girls as coast-to-coast convoy prepares to depart
By Harriet Marsden, The Week UK Published
-
Argentina: the therapy capital of the world
Under the radar Buenos Aires natives go hungry to pay for psychoanalysis, amid growing instability, anxiety – and societal acceptance
By Harriet Marsden, The Week UK Published
-
Does declining birth rate spell doom for Britain?
Today's Big Question Ageing population puts pressure on welfare state, economy and fabric of society, while fertility is rising on populist agendas
By Harriet Marsden, The Week UK Published
-
How a new blood test could revolutionise sepsis diagnosis
The Explainer Early results from ongoing trial suggest faster identification of deadly condition is possible
By The Week Staff Published
-
Kush: the drug destroying young lives in West Africa
The Explainer There has been a sharp rise in young addicts in Sierra Leone, Guinea and Liberia
By Flora Neville, The Week UK Published
-
What is life like in Gaza now?
In depth Despite starvation, a sanitation crisis, blackouts and boredom, the 'mundane drumbeat of life continues'
By Elliott Goat, The Week UK Last updated
-
What is a 'feminist approach' to cancer care?
The Explainer 800,000 women die from 'preventable' cancers each year due to 'patriarchy', landmark study finds
By Harriet Marsden, The Week UK Published